tirzepatide vs semaglutide cardiovascular outcomes of and for patients with type 2 diabetes in clinical practice semaglutide cardiovascular outcomes news 2025

Heres how the two compare at a glance: Brand names: Wegovy vs Mounjaro Active ingredient: Semaglutide vs Tirzepatide Agonist type: GLP-1 only vs Dual GLP-1/GIP UK weight management approval: September 2022 vs Late 2023 Standard dose range: 0.25mg to 2.4mg (Wegovy) vs 2.5mg to 15mg (Mounjaro) High-dose options: 7.2mg (emerging) vs 15mg (established) The standard approach for both involves gradual escalation from a lower dose to allow your body adjusts to the medication

Risk Factors for Polypharmacy There are two main categories of risk factors contributing to polypharmacy: those related to patients and those associated with the healthcare system (1,4-6)

Obesity belongs in the same category

ENYO Pharma

Then theres the risk of fakes